(Q73603362)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

phase II clinical trial

1 reference

1 reference

1 reference

D Pectasides

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

A Visvikis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

A Aspropotamitis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

A Halikia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

N Karvounis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

M Dimitriadis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

A Athanassiou

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Cancer

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

74-79

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

cites work

Cancer statistics, 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Results of surgery following radical radiotherapy for invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Chemotherapy of Metastatic Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Chemotherapy with methotrexate, carboplatin, mitoxantrone (Novantrone) and vincristine (Oncovin) in transitional-cell urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2899%2900187-2

7 January 2021

10.1016/S0959-8049(99)00187-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10741298%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference